The Elixir Bioadaptor vs. The Onyx Stent in De Novo Native Coronary Arteries

  • STATUS
    Recruiting
  • End date
    Dec 31, 2026
  • participants needed
    444
  • sponsor
    Elixir Medical Corporation
Updated on 27 June 2021
Investigator
Tina Cordaro, RN, BSN, MPA
Primary Contact
Shinkoga Hospital (0.9 mi away) Contact
+35 other location
stenosis
heart disease
unstable angina
percutaneous coronary intervention
ischemia
bypass graft
coronary angioplasty

Summary

The objective of this study is to verify the safety and efficacy of the investigational device (ELX1805J) for the treatment of ischemic heart disease due to de novo, native coronary artery lesions

Description

The Bioadaptor RCT Study is a prospective, 2:1 randomized study of parallel designed, that will enroll up to 474 patients requiring treatment of up to two de novo coronary lesions of 24 mm in length in vessels of 2.5 mm and 3.5 mm in diameter.

One or two designated target lesions, located in separate epicardial vessels (RCA, LCX or LAD), and meeting the inclusion/exclusion criteria may be treated with the ELX1805J (DynamX Bioadaptor) or Resolute Onyx stent

The primary safety endpoint is Target Lesion Failure (TLF) at 12 months. TLF is a composite endpoint defined as cardiac death, target vessel MI, and clinically-indicated target lesion revascularization

Additional secondary safety and effectiveness endpoints will be evaluated at 30 days, 6 and 12 months and 2-5 years.

Using visual assessment, the target lesion must measure 2.5 mm and 3.5 mm in diameter and 24 mm in length able to be covered by a single ELX1805J or Resolute Onyx stent including 2 mm of healthy vessel on either side of the planned treatment area.

The patient will be eligible for device implantation only after satisfactory lesion pre-dilatation defined as: TIMI 2 flow, and no dissection greater than Grade B (NHLBI) able to be covered with a single device

Details
Condition Coronary Artery Disease, Coronary heart disease, Coronary Artery Stenosis, Ischemic Heart Disease, Cardiac Ischemia, Myocardial Ischemia, coronary disease, disease, coronary, coronary heart diseases, coronary stenosis
Treatment Percutaneous coronary intervention
Clinical Study IdentifierNCT04192747
SponsorElixir Medical Corporation
Last Modified on27 June 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

General Inclusion Criteria
Patients who meet all of the following criteria are eligible
Patient must be 20 years of age
Patient must have evidence of myocardial ischemia (e.g., stable or unstable angina, silent ischemia, positive functional study or electrocardiogram (ECG) changes consistent with ischemia)
Patients who are able to take dual anti-platelet therapy for 1 year following the index procedure and anticoagulants prior to/during the index procedure
The subject is an acceptable candidate for Percutaneous Transluminal Coronary Angioplasty (PTCA), stenting, and emergent Coronary Artery Bypass Graft (CABG) surgery
The subject or subject's legally authorized representative has been informed of the nature of the study and agrees to its provisions and has provided written informed consent as approved by the Institutional Review Board or Ethics Committee of the respective clinical site
Women of childbearing potential with a negative pregnancy test within 7 days and women who are not pregnant or nursing
Patient must agree to undergo all clinical study required follow up visits, angiograms, and imaging testing
Patient must agree not to participate in any other clinical research study for a period of one year following the index procedure
Target lesion(s) must be de novo and located in a native coronary artery with a vessel mean diameter of 2.5 and 3.5 mm
Target lesion(s) must be in a major artery or branch with a visually estimated stenosis of 50% and < 100% with a TIMI flow of > 1\. When two target lesions are treated, they must be located in separate major epicardial vessels
visually estimated target lesion length is 10 to 24 mm and must be able to be covered by a single 14 to 28 mm ELX1805J stent and have at least 2 mm of healthy vessel on either side Or
The visually estimated target lesion length is 10 to 24 mm and must be able to be covered by a single 14 to 30 mm ZES stent respectively and have at least 2 mm of healthy vessel on either side
The lesion(s) must be successfully pre-dilated prior to enrollment Mandatory pre-dilatation includes the use of 2 orthogonal views to confirm lesion inclusion and exclusion criteria and successful pre-dilatation defined as balloon inflation without waist and a lumen diameter no less than 0.5 mm smaller than the vessel diameter
Percutaneous intervention of lesions in a non-target vessel if
Not part of a another clinical investigation
days prior to the study index procedure
months after the study index procedure (planned)
Percutaneous intervention of lesions located in the target vessel if
Not part of a clinical investigation
months prior to the study index procedure
>12 months after the study index procedure (planned)
Previous intervention was distal to and >10 mm from the target lesion

Exclusion Criteria

The patient was diagnosed with an acute myocardial infarction within the past 72 hours and the CK and CKMB have not returned to normal (or cTn >15x ULN) and the patient is experiencing clinical symptoms indicative of ongoing ischemia
Patient has a known hypersensitivity or contraindication to aspirin, both heparin and bivalirudin, clopidogrel, prasugrel or ticagrelor, cobalt, nickel, chromium, molybdenum, PLLA polymers or contrast sensitivity that cannot be adequately pre-medicated
Patients with a history of allergic reaction or serious hypersensitivity to drugs exhibiting interactions with sirolimus, zotarolimus, everolimus, tacrolimus, temsirolimus, biolimus and other rapamycin, derivatives or analogues) or similar drugs
Elective surgery is planned within the first 6 months after the procedure that will require discontinuing either aspirin or clopidogrel or other P2Y12 inhibitors
Patient presenting with chronic atrial or ventricular arrhythmia or current unstable ventricular arrhythmias
Patient has a previous diagnosis of COPD; emphysema or chronic bronchitis
Patient has a known left ventricular ejection fraction (LVEF) < 30%
Patient has received a heart or other organ transplant or is on a waiting list for any organ transplant
Patient has a malignancy that is not in remission
Patient is receiving immunosuppression therapy other than steroids and has known immunosuppressive or autoimmune disease (e.g. human immunodeficiency virus, systemic lupus erythematosus etc.)
Patient is receiving chronic anticoagulation therapy (e.g., heparin, coumadin) that cannot be stopped and restarted according to local hospital standard procedures
Patient has a platelet count < 100,000 cells/mm3 or > 700,000 cells/mm3, a WBC of < 3,000 cells/mm3, or documented or suspected to have cirrhosis of Child-Pugh Class B within 7 days before study procedure
Patient has known renal insufficiency (e.g., serum creatinine level of more than 2.5 mg/dL within 7 days before study procedure, or patient on dialysis)
Patient has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions
Patient has had a cerebrovascular accident (CVA) or transient ischemic neurological attack (TIA) within the past six months
Patient has had a significant GI or urinary bleed within the past six months
Patient has severe symptomatic heart failure (i.e., NYHA class IV)
Patient has a medical condition that precludes safe 6 French sheath insertion
Patient has other medical illness or known history of substance abuse (alcohol, cocaine, heroin etc.) that may cause non-compliance with the clinical study plan, confound the data interpretation or is associated with a limited life expectancy (i.e., less than one year)
Patient is already participating in another clinical research study which has not reached the primary endpoint (long-term follow-up is not an exclusion)
Other patients whom primary investigator or subinvestigator determined to be ineligible for this clinical study
Patients with bypass graft to the target vessel or lesion is located in a bypass graft
Patients with stent implanted within 10 mm of proximal or distal end of target lesion
Patients with a target lesion involving a bifurcation of which the side branch will be jailed by the struts and
Side branch 2 mm in diameter
Side branch requiring predilatation (including Kissing Balloon Technique), or
Side branch requiring protection guide wire (e.g. ostial lesion > 50% stenosed)
Patients suspected or confirmed with the QCA analysis of having stenotic lesion of more than 50% in target vessel in addition to target lesion
Patients with target lesion in ostia located within 5 mm of origin of LAD, LCX or RCA
Patients with stenotic lesion in left main trunk
Patients with target lesion that is a chronic total occlusion (CTO) or TIMI 1 coronary flow in the target vessel
Patients with target vessel that contains thrombus as indicated in pre-procedure angiographic, IVUS or OCT images
Excessive tortuosity two 45 angles or extreme angulation ( 90) proximal to or within the target lesion
Patients with target vessel that has moderate to severe calcification that prevents complete angioplasty balloon (POBA with non-compliant balloon, or scoring balloon,) inflation or requires other devices such as rotational atherectomy, rotoblator
Patients with dissection of Grade A or B that cannot be covered (including 2mm distal to the dissection) with a single study device or with dissection of Grade C or higher
Patients with 2 or more target lesions on 1 branch or target lesions on 3 branches that need to be treated during study procedure
Target lesion involves a myocardial bridge
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note